Live Breaking News & Updates on Ikarian Capital

Stay updated with breaking news from Ikarian capital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

BiomX (NYSEMKT:PHGE) Now Covered by Analysts at Laidlaw

Laidlaw started coverage on shares of BiomX (NYSEMKT:PHGE – Free Report) in a report released on Tuesday, Benzinga reports. The brokerage issued a buy rating and a $2.50 price objective on the stock. Separately, HC Wainwright reaffirmed a buy rating and set a $2.00 price target on shares of BiomX in a report on Tuesday, […] ....

Ikarian Capital , Biomx Inc , Exchange Commission , Free Report , Get Free Report , Biomx Daily ,

Achilles Therapeutics plc (NASDAQ:ACHL) Short Interest Down 42.5% in May

Achilles Therapeutics plc (NASDAQ:ACHL – Get Free Report) was the target of a large decline in short interest in May. As of May 15th, there was short interest totalling 13,800 shares, a decline of 42.5% from the April 30th total of 24,000 shares. Approximately 0.0% of the shares of the stock are sold short. Based […] ....

Piper Sandler , Fcpm Iii Services , Acadian Asset Management , Ikarian Capital , Achilles Therapeutics , Get Free Report , Point Capital , Asset Management , Vestal Point Capital , Achilles Therapeutics Daily ,

Short Interest in Achilles Therapeutics plc (NASDAQ:ACHL) Drops By 42.5%

Achilles Therapeutics plc (NASDAQ:ACHL – Get Free Report) saw a significant drop in short interest in the month of May. As of May 15th, there was short interest totalling 13,800 shares, a drop of 42.5% from the April 30th total of 24,000 shares. Based on an average daily trading volume, of 396,500 shares, the short-interest […] ....

Piper Sandler , Ikarian Capital , Acadian Asset Management , Fcpm Iii Services , Achilles Therapeutics Company Profile , Achilles Therapeutics , Get Free Report , Point Capital , Asset Management , Achilles Therapeutics Daily ,

iBio (NYSE:IBIO) Earns Buy Rating from Analysts at Chardan Capital

Chardan Capital assumed coverage on shares of iBio (NYSE:IBIO – Free Report) in a report released on Tuesday, MarketBeat.com reports. The brokerage issued a buy rating and a $5.00 price target on the stock. Separately, StockNews.com started coverage on iBio in a research note on Saturday, April 20th. They issued a sell rating for the […] ....

United States , Bio Inc , Ikarian Capital , Opaleye Management Inc , Chardan Capital , Free Report , Bio Trading Down , Get Free Report , Opaleye Management , Bio Daily ,